Organization (Industry)
ABBOTT DIABETES CARE LIMITED
ClinicalTrials.gov lists ABBOTT DIABETES CARE LIMITED as lead sponsor of 43 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Abbott Laboratories, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers ABBOTT DIABETES CARE LIMITED: 43 lead-sponsored trials and 2 legal-entity registrations. Part of ABBOTT LABORATORIES.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (11)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 67 |
| Diabetes Mellitus, Type 2 | 25 |
| Diabetes Mellitus, Type 1 | 14 |
| Hypoglycemia | 6 |
| Hyperglycemia | 2 |
Showing 5 of 11 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 5 |
| 2021 | 8 |
| 2020 | 7 |
| 2019 | 1 |
| 2018 | 5 |
| 2017 | 5 |
Showing 10 of 21 years.
Recruitment duration, a model prediction: none of the 43 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 27% hit target (n=15) | 60% on time (n=15) |
FDA warning letters (1)
| Issue date | Letter |
|---|---|
| 2026-01-23 | abbott-diabetes-care-inc-722046-01232026 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| OAI | 14 |
FDA recalls (18)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| FreeStyle Libre 3 Sensor REF 72081-01 UDI-DI code: 00357599818005 The FreeStyle Libre 3 sensor is a component of the FreeStyle Libre 3 Continuous Glucose Monitoring System. | Class I | 2025-11-24 |
| FreeStyle Libre 3 Plus Sensor REF 78768-01 UDI-DI code: 00357599844011 The FreeStyle Libre 3 Plus sensor is a component of the FreeStyle Libre 3 Continuous Glucose Monitoring System. | Class I | 2025-11-24 |
| FreeStyle Libre 3 Plus Sensor REF 78769-01 UDI-DI code: 00357599843014 The FreeStyle Libre 3 Plus sensor is a component of the FreeStyle Libre 3 Continuous Glucose Monitoring System. | Class I | 2025-11-24 |
| FreeStyle Libre 3 Plus Sensor REF 72080-01 UDI-DI code: 00357599819002 The FreeStyle Libre 3 Plus sensor is a component of the FreeStyle Libre 3 Continuous Glucose Monitoring System. | Class I | 2025-11-24 |
| FreeStyle Libre 3 Sensors, REF: 72081-01, component of the FreeStyle Libre 3 Continuous Glucose Monitoring System | Class I | 2024-07-24 |
Showing 5 of 18 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 6 | 2023-08-10 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ABBOTT DIABETES CARE INC. | ALAMEDA, US | FDA | |
| ABBOTT DIABETES CARE LIMITED | WITNEY OXON Oxfordshire, GB | FDA | Abbott Diabetes Care Limited |
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| ABBOTT DIABETES CARE | Certificate of waiver | Terminated |
Biomarker capability evidence (41)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| DPP4 | Trial sponsor | Named in trial inclusion criteria |
| DPP4 | Trial collaborator | Named in trial inclusion criteria |
| GAD2 | Trial collaborator | Named in trial inclusion criteria |
| GBA3 | Trial collaborator | Named in trial inclusion criteria |
| GEM | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 41 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, and organization relationships.
Counted at group level under Abbott Laboratories: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.